Chronic lymphocytic leukemia (CLL) treatment has evolved from traditional chemotherapy to targeted therapies, such as Bruton tyrosine kinase (BTK) and BCL-2 inhibitors with significant improvements in survival rates and a transformation of CLL into a manageable, chronic condition. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.